FDA Lifts Clinical Hold On Lpath’s Wet-AMD Drug Isonep
This article was originally published in The Pink Sheet Daily
The San Diego biotech gets clearance from regulatory authorities to restart Phase II trials for its lead compound after a clinical hold delayed progress.
You may also be interested in...
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Option deal provides $14 million upfront plus cost-sharing arrangement for previously cash-strapped biotech.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.